The TLX102 treatment, resulting from the collaboration between Telix Pharmaceuticals (Australia), Osaka University (Japan) and the SIRIC ILIAD nuclear medicine
The “Tumour targeting, Imaging, radiotherapies network” of the Cancéropôle Grand-Ouest is pleased to announce its fourteenth international workshop dedicated